Brief: Oragenics Updates Shareholders On Concussion Drug Progress
09/10/2024 12:57
Oct 9 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS, INC. UPDATES SHAREHOLDERS ON CONCUSSION DRUG
PROGRESS
AND PHASE II TRIAL PREPARATION
* ORAGENICS INC - PREPARING TO INITIATE PHASE II CLINICAL
TRIALS
FOR ONP-002
* ORAGENICS: IN PREPARATION FOR UPCOMING PHASE II CLINICAL
TRIALS
PLANS TO SUBMIT AUSTRALIAN REGULATORY SUBMISSION BROCHURE DURING
Q4
Source text for Eikon: ID:nGNX3X11BT
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing